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Edited by Lukas HuberAbstract The dysregulation of Wnt/b-catenin signaling and
subsequent upregulation of b-catenin response transcription
(CRT) occur frequently in colon cancer cells. Non-steroidal
anti-inﬂammatory drugs (NSAIDs) can repress CRT in colorec-
tal cancer, but little is known about the mechanism of action. We
show that the NSAID diclofenac inhibits Wnt/b-catenin signal-
ing without altering the level of b-catenin protein and reduces
the expression of b-catenin/TCF-dependent genes. Diclofenac in-
duced the degradation of IjBa, which increased free nuclear fac-
tor jB (NF-jB) in cells. Also, the ectopic expression of p65,
which is a component of NF-jB, suppressed CRT. Our ﬁndings
suggest that diclofenac inhibits Wnt/b-catenin signaling via the
activation of NF-jB in colon cancer cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Epidemiological studies have indicated that non-steroidal
anti-inﬂammatory drugs (NSAIDs), including indomethacin,
aspirin, and sulindac, have anti-cancer activity in colorectal
cancer [1,2]. Although cyclooxygenase-2 (COX-2) is the molec-
ular target of NSAIDs, accumulating evidence suggests that
NASIDs inhibit cell proliferation through a COX-2 indepen-
dent mechanism [3]. Recently, aspirin has been found to
activate the nuclear factor jB (NF-jB) pathway and this
mechanism is important for aspirin-mediated growth inhibi-
tion in colon cancer cells [4]. NF-jB is composed of two
subunits, p65 and p50, and is normally sequestered in the cyto-
sol by an inhibitory protein, IjBa [5]. The stimulation of theAbbreviations: NF-jB, nuclear factor jB; NSAID, non-steroidal anti-
inﬂammatory drug; Wnt3a CM, Wnt3a conditioned medium; CRT, b-
catenin response transcription; hFz-1, human Frizzled-1; MMP7,
matrix metalloproteinase 7; FBS, fetal bovine serum
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doi:10.1016/j.febslet.2005.06.049NF-jB pathway results in the phosphorylation and subsequent
degradation of IjBa, which then allows free NF-jB to translo-
cate to the nucleus [6].
The abnormal activation of the Wnt/b-catenin pathway is a
frequent early event in intestinal epithelial cells during the
development of colon cancer [7,8]. Mutations of the adenoma-
tous polyposis coli gene occur in the majority of sporadic colo-
rectal cancers as well as in familial adenomatous polyposis
[9,10]. In addition, mutations in the b-catenin gene have been
observed in colorectal cancer and melanoma [11]. Common
sites of b-catenin mutations are the phosphorylation motifs
in its N-terminal domain. These mutations lead to an excessive
accumulation of b-catenin in the nucleus and to stimulation of
its target genes, including cyclin D1, myc, matrix metallopro-
teinase-7 (MMP7), and peroxisome proliferator-activated
receptor d, which play important roles in colorectal tumorigen-
esis [12–15]. Thus, the constitutive activation of b-catenin re-
sponse transcription (CRT) is a potential target for
chemoprevention and treatment of colorectal cancer. In colo-
rectal cancer cells, NSAIDs have been shown to attenuate
CRT through several mechanisms [16–18].
In the present study, we investigated the molecular mecha-
nism of the diclofenac-mediated inhibition of Wnt/b-catenin
signaling. Diclofenac may suppress CRT through cross-regula-
tion of the Wnt/b-catenin and NF-jB pathways in colon can-
cer cells.2. Materials and methods
2.1. Chemicals and plasmids
Diclofenac, sulindac, and aspirin were purchased from Sigma (St.
Louis, MO) and were then dissolved in DMSO. LiCl was obtained
from Sigma. Human Frizzled cDNA was cloned from SW480 cDNA
(Clonetech) by PCR and was then subcloned into pCDNA3.1 (Invitro-
gen). The pTOPﬂash reporter plasmid was obtained from Upstate
Biotechnology (Lake Placid, NY). Reporter plasmids containing the
cyclin D1 and MMP7 promoters were prepared by amplifying the pro-
moter regions, which harbored TCF-4 response elements, by PCR and
insertion into pRL-null vectors, yielding pCyclinD1-RL and pMMP7-
RL. pCMV-RL and pSV40-FL plasmids were purchased from
Promega.2.2. Cell culture, transfection, and luciferase assay
L cells that secrete Wnt3a, HEK293 cells, and HCT116 cells were
obtained from the American Type Culture Collection and maintained
in DMEM supplemented with 10% fetal bovine serum (FBS), 120 lgblished by Elsevier B.V. All rights reserved.
4214 M. Cho et al. / FEBS Letters 579 (2005) 4213–4218penicillin/ml, and 200 lg streptomycin/ml. Wnt3a conditioned medium
(Wnt3a CM) was prepared by culturing Wnt3a-secreting L cells in
DMEM with 10% FBS for 4 days. The medium was harvested and
sterilized using a 0.22-lm ﬁlter. Fresh medium was added and the cells
were cultured for another 3 days. The medium was again collected and
combined with the previous medium. The transfections were carried
out with Lipofectamine 2000 (Invitrogen) according to the manufac-
turers instructions. Luciferase assays were performed using the Dual
Luciferase assay kit (Promega).Fig. 1. Diclofenac inhibits Wnt/b-catenin signaling without altering b-catenin
incubated with aspirin (2, 4, 8 mM), sulindac (200, 400, 600 lM), or diclofena
diclofenac (200, 400, 600 lM) for 24 h in the presence of 20 mM LiCl (B), a
prepared from HEK293 cells treated with either vehicle (DMSO) or diclofen
subjected to Western blotting with anti-b-catenin antibody. (D) HCT116
increasing amounts of diclofenac (200, 400, 600 lM) were added to the tra
Cytosolic proteins were prepared from HCT116 cells treated with vehicle (DM
catenin antibody. (C,E) The blots were reprobed with anti-actin antibody as a
experiments; the bars indicate standard deviations.2.3. Immunoprecipitation
Immunoprecipitation was performed with 2 lg of anti-b-catenin
antibody in 1 mg of cell extracts. The samples were pre-cleared using
protein A–agarose (Roche) and incubated with antibody against b-
catenin for 2 h at 4 C. After the addition of protein A–agarose, the
samples were further incubated overnight at 4 C. After three washes
with phosphate-buﬀered saline containing 0.1% NP 40, the beads were
resuspended in SDS sample buﬀer and then subjected to Western blot
analysis.levels. (A,B) HEK293 cells transfected with TOPﬂash and hFz-1 were
c (200, 400, 600 lM) for 24 h in the presence of Wnt3a CM (A), or with
nd the luciferase activity was determined. (C) Cytosolic proteins were
ac (600 lM) in the presence or absence of LiCl (20 mM) and were then
cells were co-transfected with TOPﬂash. At 24 h after transfection,
nsfected cells for 24 h, and the luciferase activity was measured. (E)
SO) or diclofenac (200, 400, 600 lM) for Western blotting with anti-b-
loading control. (A,B,D) The results are shown as the average of three
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The cytosolic and nuclear fraction was prepared as previously
described [19]. Proteins were separated by 4–12% gradient SDS–PAGE
(Invitrogen) and transferred to a nitrocellulose membrane (Amersham
Biosciences). The membranes were blocked with 5% nonfat milk and
probed with anti-b-catenin (BD Transduction Laboratories), anti-p65
(Santa Cruz Biotechnology), anti-IjBa (Cell Signaling Technology),
anti-cyclin D1 (Santa Cruz Biotechnology), and anti-actin antibodies
(Cell Signaling Technology). After washing, the membranes were
incubated with horseradish peroxidase-conjugated anti-mouse IgG or
anti-rabbit IgG (Santa Cruz Biotechnology) and the bands were visual-
ized using the ECL system (Santa Cruz Biotechnology).
2.5. Immunoﬂuorescence analysis
HCT116 cells were cultured on glass chamber slides and treated with
either DMSO or diclofenac for 24 h. After treatment, the cells were
washed with PBS, ﬁxed with 4% formaldehyde, permeabilized in 0.3%
TritonX-100, and blocked in 4%bovine serumalbumin for 1 h. The cells
were stained with anti-p65 antibody and DAPI and then analyzed by
confocal microscopy using a Zeiss LSM510 Meta microscope.
2.6. Cell viability assay
Cells were inoculated into 96-well plates and treated with diclofenac
for 24 h. The cell viability from each treated sample was measured in
triplicate using Celltiter-Glo assay kit (Promega) according to the
manufacturers instructions.3. Results
3.1. Diclofenac inhibits Wnt/b-catenin signaling
To investigate the eﬀect of NSAIDs onWnt/b-catenin signal-
ing, HEK293 cells transfected with TOPﬂash and human Friz-Fig. 2. Expression of b-catenin target genes is downregulated by diclofenac.
D1-RL (B). At 24 h after transfection, increasing amounts of diclofenac (20
luciferase activity was measured. The results are shown as the average of thr
were prepared from HCT116 cells treated with diclofenac (200, 400, 600 lM
blot was reprobed with anti-actin antibody as a loading control. (D) HCT11
600 lM) and cell viability was determined by Celltiter-Glo assay (Promega).zled-1 (hFz-1) expression plasmids were incubated with
aspirin, sulindac, or diclofenac in the presence of Wnt3a CM.
As shown in Fig. 1A, treatment with NSAIDs resulted in a
dose-dependent decrease of the CRT that had been induced by
Wnt3a CM. Among the NSAIDs tested, diclofenac was the
strongest inhibitor ofWnt/b-catenin signaling, repressing about
70% of CRT at a concentration of 400 lM (Fig. 1A). Therefore,
diclofenac was used in the subsequent experiments to study the
mechanism by which it represses CRT activated by Wnt3a.
3.2. Diclofenac does not aﬀect the level of b-catenin
To identify the site of action of diclofenac in Wnt/b-catenin
signaling, transfected HEK293 cells were incubated with dic-
lofenac and LiCl, which speciﬁcally inhibits GSK 3b and thus
increases b-catenin levels [20]. As shown in Fig. 1B, diclofenac
was still able to inhibit LiCl-induced CRT. Therefore, diclofe-
nac must inhibit Wnt/b-catenin signaling by acting on b-cate-
nin itself or its downstream elements. In Wnt/b-catenin
signaling, CRT is largely dependent on the level of b-catenin,
which in turn is regulated by ubiquitin-dependent degradation
[21]. A previous report implied that some NSAIDs, such as
indomethacin, decrease the amount of b-catenin protein [17].
To explore the possibility that diclofenac acts on b-catenin
itself, the intracellular b-catenin levels in HEK293 cells treated
with diclofenac were determined. Western blot analysis using
b-catenin antibody showed that diclofenac did not aﬀect the le-
vel of b-catenin that accumulated in the presence of LiCl
(Fig. 1C). The eﬀect of diclofenac on CRT was also examined
in HCT116 colon cancer cells, which contain a Ser-45 deletion(A,B) HCT-116 cells were co-transfected with MMP7-RL (A) or cyclin
0, 400, 600 lM) were added to the transfected cells for 24 h, and the
ee experiments; the bars indicate standard deviations. (C) Cell lysates
) and subjected to Western blotting with anti-cyclin D1 antibody. The
6 cells were incubated with increasing amounts of diclofenac (200, 400,
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ted with TOPﬂash plasmid and then treated with increasing
amounts of diclofenac. As in the HEK293 cells, diclofenac re-
pressed CRT in HCT116 cells (Fig. 1D) and the level of b-cate-
nin was unchanged in response to diclofenac (Fig. 1E). These
results indicate that diclofenac inhibits Wnt/b-catenin signal-
ing without altering the b-catenin level.3.3. Diclofenac represses the expression of b-catenin-dependent
genes
To determine whether diclofenac aﬀects the expression of b-
catenin-dependent genes, the promoter activities of cyclin D1
and MMP7, which are known b-catenin target genes [12,14],
were evaluated. Reporter constructs containing 360 bp of the
cyclin D1 or 190 bp of the MMP7 promoter regions were
transfected into HCT116 cells, which were subsequently trea-
ted with increasing amounts of diclofenac for 24 h. As shown
in Fig. 2A and B, diclofenac downregulated cyclin D1 and
MMP7 promoter activities. In parallel with this experiment,
cyclin D1 protein levels were analyzed in diclofenac-treated
cells. Consistent with the results of the luciferase reporter as-
say, the Western blot analysis showed that the expression of
cyclin D1 protein was decreased in a concentration-dependent
manner following incubation with diclofenac (Fig. 2C). Several
studies have reported that the disruption of b-catenin function
reduced the cell growth of human colon cancer cells [22,23].
Thus, we examined the eﬀect of diclofenac on the growth of
HCT116 colon cancer cell. The cells were incubated with var-
ious concentrations of diclofenac and cell viability was deter-
mined. As shown in Fig. 2D, diclofenac reduced the viability
of HCT116 cells in a dose-dependent manner.
Fig. 3. Diclofenac induces the degradation of IjBa and the nuclear
translocation of NF-jB. (A) Diclofenac induces IjBa degradation.
Lysates from HCT116 cells treated with diclofenac (200, 400, 600 lM)
were subjected to Western blotting with anti-IjBa antibody. (B)
Diclofenac induces nuclear translocation of NF-jB. The cellular
location of NF-jB in HCT116 cells treated with DMSO and diclofenac
(600 lM) was determined by immunoﬂuorescence analysis. After
ﬁxation, the cells were stained with DAPI and anti-p65 antibody and
observed at 400· magniﬁcation. (C) Nuclear proteins from HCT116
cells treated with diclofenac (200, 400, 600 lM) were subjected to
Western blotting with anti-p65 antibody. (A,C) The blots were
reprobed with anti-actin antibody as a loading control.3.4. Diclofenac activates the NF-jB pathway
It was reported that aspirin activates NF-jB signaling and
induces apoptosis in colon cancer cells [24]. Therefore, the abil-
ity of diclofenac to stimulate NF-jB signaling in HCT116 cells
was investigated. The cytoplasmic levels of IjBa, the NF-jB
inhibitor protein, were determined by incubating HCT116 cells
with diclofenac for 24 h and then carrying out Western blot
analysis using anti-IjBa antibody. As shown in Fig. 3A, treat-
ment with diclofenac led to a reduction of cytoplasmic IjBa
protein levels. It is known that the degradation of IjBa results
in the translocation of NF-jB into the nucleus, followed by the
induction of a wide variety of genes involved in inﬂammation,
cell proliferation, and apoptosis [25–27]. Therefore, we next
examined the location of NF-jB in diclofenac-treated cells.
Immunoﬂuorescence analysis using anti-p65 antibody showed
that p65, a subunit of NF-jB, was primarily detected in the
cytoplasm in vehicle (DMSO)-treated cells (Fig. 3B). However,
upon treatment with diclofenac, the nuclear accumulation of
p65 was observed in HCT116 cells (Fig. 3B). We also deter-
mined diclofenac-induced nuclear translocation of NF-jB by
Western blot analysis. In agreement with immunoﬂuorescence
analysis, the level of p65 in nuclear fraction was increased in
response to treatment of diclofenac (Fig. 3C). Thus, treatment
with diclofenac induces the degradation of IjBa and allows
free NF-jB to translocate to the nucleus.
3.5. NFjB induces the downregulation of CRT
A previous report demonstrated that b-catenin inhibits NF-
jB activity through a physical interaction [28]. We thereforehypothesized that NF-jB, which is released from the IjBa
complex upon treatment with diclofenac, inhibits b-catenin
activity. This possibility was tested by co-transfecting p65,
hFz-1, and TOPﬂash plasmids into HEK293 cells, followed
by incubation with Wnt3a CM. As shown in Fig. 4A, the over-
expression of p65 decreased CRT activated by Wnt3a CM.
The level of intracellular b-catenin in cells overexpressing
p65 was then examined. Western blot experiments showed that
the level of p65 protein was increased in cells transfected with
the p65 expression plasmid compared with the levels in cells
transfected with mock plasmid (Fig. 4B). However, the level
of b-catenin protein was unaﬀected by p65 overexpression
(Fig. 4B). Consistent with this ﬁnding, the ectopic expression
of p65 repressed CRT in HCT116 cells (Fig. 4C). We then
tested whether b-catenin interacted with p65 by co-immuno-
precipitation experiments. As shown in Fig. 4D, b-catenin
formed a complex with p65. These results indicate that the
activation of the NF-jB pathway may suppress Wnt/b-catenin
signaling through a physical interaction with b-catenin.
Fig. 5. Model for diclofenac-mediated inhibition of Wnt/b-catenin
signaling. Treatment of diclofenac leads to the degradation of IjBa;
dissociated NF-jB then inhibits the b-catenin activity that stimulates
b-catenin response transcription.
Fig. 4. NF-jB suppresses Wnt/b-catenin signaling. (A) HEK293 cells
were co-transfected with TOPﬂash, hFz-1, and increasing amounts of
p65 expression plasmids. At 24 h after transfection, the cells were
incubatedwithWnt3aCMornormalmedium for 24 h, and the luciferase
activity was measured. (B) Cytosolic proteins were prepared from
transfected cells and subjected to Western blotting with anti-b-catenin
and anti-p65 antibodies. The blot was reprobed with anti-actin antibody
as a loading control. (C) HCT116 cells were co-transfected with
TOPﬂash and pCMV-p65. At 48 h after transfection, the luciferase
activity was measured. The results are shown as the average of three
experiments; the bars indicate standard deviations. (D) Cytosolic
proteins from HEK293 cells overexpressing p65 and b-catenin were
immunoprecipitated with anti-b-catenin antibody (normal IgG as a
negative control). Proteins in the b-catenin complex were analyzed by
Western blotting with anti-b-catenin and anti-p65 antibodies.
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Multiple molecular mechanisms seem to be involved in the
chemopreventive eﬀects of NSAIDs. In this study, a novelmechanism of action was proposed for the inhibition of
CRC cell growth by diclofenac. Diclofenac inhibited CRT
through a GSK-3b-independent mechanism. In contrast to
the result of a previous study in which indomethacin treatment
resulted in decreased b-catenin protein expression [17], a simi-
lar decrease in response to diclofenac was not observed. It was
reported that aspirin and indomethacin induce the N-terminal
phosphorylation of b-catenin [29] and that the phosphorylated
b-catenin then forms a transcriptionally inactive complex with
lymphoid enhancer-binding factor-1 [30]. However, our results
showed that diclofenac also inhibits CRT in HCT116 cells,
which have a mutation in the N-terminal phosphorylation site
of b-catenin. Therefore, it is possible that mechanisms other
than those previously proposed are involved in diclofenac-
mediated CRT inhibition.
Previous studies have proposed cross-regulation between the
NF-jB and Wnt/b-catenin pathways [28,31]. Therefore, the
NF-jB pathway may be a target mechanism for diclofenac-
mediated CRT inhibition. In the present study, diclofenac in-
duced the degradation of IjB, leading to the accumulation
of free NF-jB in cells. Furthermore, the ectopic expression
of NF-jB was found to inhibit CRT, suggesting that diclofe-
nac inhibits Wnt/b-catenin signaling via the activation of
NF-jB in colon cancer cells. Importantly, the co-immunopre-
cipitation experiment showed that b-catenin interacted with
p65. It is possible that this interaction inhibits b-catenin activ-
ity by inhibiting the formation of a transcriptionally active
complex containing TCF-4 and p300. Related to this, it was re-
ported that NO-donating aspirin inhibits TCF/LEF-dependent
transcription by disrupting the association between nuclear b-
catenin and TCF-4 [18].
Although NSAIDs have a protective eﬀect against colorectal
cancer, their harmful side eﬀects, such as gastric mucosal dam-
age, restrict their potential use as chemopreventive agents. The
results reported here indicate that diclofenac inhibits Wnt/b-
catenin signaling in colon cancer cells through the activation
of NF-jB (Fig. 5). Thus, small molecules that activate the
NF-jB pathway may function as negative regulators of Wnt/
b-catenin signaling and may act as antineoplastic therapeutics
in colon cancer.Acknowledgment: This work was supported by a 2004 Inje University
Research Grant.References
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